<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763044</url>
  </required_header>
  <id_info>
    <org_study_id>2020154</org_study_id>
    <nct_id>NCT04763044</nct_id>
  </id_info>
  <brief_title>Evaluation of the Fluoride Dose Response Using In Situ Caries Model</brief_title>
  <official_title>Evaluation of the Fluoride Dose Response of MFP Dentifrice Using In Situ Caries Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Procter and Gamble</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the fluoride dose response of different dentifrice&#xD;
      fluoride concentrations - 0, 250, 1100 and 2800 ppm fluoride as sodium monofluorophosphate&#xD;
      (MFP) using an in situ caries model.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">July 21, 2021</completion_date>
  <primary_completion_date type="Actual">July 21, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Fifth leg of the study will not be randomized, participants will remain blinded but all will use the same product.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Enamel Fluoride Uptake (EFU)</measure>
    <time_frame>Evaluations will occur after 21 days of product use</time_frame>
    <description>The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by [Sakkab et al., 1984]. The calculated scores will be measured in μg F/cm2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Enamel Fluoride Uptake (EFU)</measure>
    <time_frame>Evaluations will occur after 7 and 14 days of product use</time_frame>
    <description>The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by [Sakkab et al., 1984]. The calculated scores will be measured in μg F/cm2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Surface Microhardness (SMH)</measure>
    <time_frame>Evaluations will occur after 7, 14 and 21 days of product use</time_frame>
    <description>The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Caries</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1100 ppm SnF2 toothpaste only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0 ppm F</intervention_name>
    <description>Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_label>Period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>250 ppm F as MFP</intervention_name>
    <description>Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_label>Period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1100 ppm as MFP</intervention_name>
    <description>Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_label>Period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2800 ppm F as MFP</intervention_name>
    <description>Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_label>Period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1100 ppm SnF2</intervention_name>
    <description>Each subject will be assigned to this treatment during the fifth period for this crossover study.</description>
    <arm_group_label>Period 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be between 18 and 85 years of age;&#xD;
&#xD;
          -  Provide written informed consent prior to participation and be given a signed copy of&#xD;
             the informed consent form;&#xD;
&#xD;
          -  Be in general good health as determined by the Investigator based on a review of the&#xD;
             health history/update for participation in the trial;&#xD;
&#xD;
          -  Be wearing a removable mandibular partial denture with sufficient room in one&#xD;
             posterior buccal flange area to accommodate two 4 mm round enamel specimens and room&#xD;
             on the same side to accommodate two 4 mm round specimens in the buccal surface of two&#xD;
             posterior denture teeth;&#xD;
&#xD;
          -  Be willing and capable of wearing their removable partial denture 24 hours a day for&#xD;
             four (4), three-week treatment periods;&#xD;
&#xD;
          -  Be willing to allow study personnel to drill specimen sites (as described in #iv) in&#xD;
             their mandibular partial denture;&#xD;
&#xD;
          -  Be in good medical and dental health with no active caries or periodontal disease&#xD;
             (NOTE: subjects presenting at screening with caries may continue in the study if their&#xD;
             carious lesions are restored prior to beginning treatment 1);&#xD;
&#xD;
          -  Have a salivary flow rate in the range of normal values (unstimulated whole saliva&#xD;
             flow rate ≥ 0.2 mL/min; gum base stimulated whole saliva flow rate ≥ 0.8 mL/min).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently being pregnant, intending to become pregnant during the study period, or&#xD;
             breast feeding;&#xD;
&#xD;
          -  Currently having any medical condition that could be expected to interfere with the&#xD;
             subject's safety during the study period;&#xD;
&#xD;
          -  Currently taking antibiotics or having taken antibiotics in the two weeks prior to&#xD;
             beginning treatment 1;&#xD;
&#xD;
          -  Having participated in another clinical study or receipt of an investigational drug&#xD;
             within 30 days of beginning treatment 1; or&#xD;
&#xD;
          -  Taking fluoride supplements, required to use a fluoride mouth rinse, or have received&#xD;
             a professional fluoride treatment in the two weeks preceding specimen placement;&#xD;
&#xD;
          -  Currently taking or have ever taken bisphosphonate drugs (e.g., Fosamax, Actonel and&#xD;
             Boniva) for the treatment of osteoporosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oral Health Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

